Sep 2022 $8 M No. 35 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 35, Sep 2022 × Investors in this round 1 investor had bought by the notice of Sep 28, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer Hermanus Kieftenbeld · Executive Officer · Chief Financial Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Nicole Kelsey · Executive Officer · Chief Legal Officer & Secretary Ana John Dutra · Director Frank John Kung · Director Geoffrey John Duyk · Director James John Mccann · Director Julie John Washington · Director L John Doerr · Director Lisa John Qi · Director Philip John Eykerman · Director Ryan John Panchadsaram · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by Issuer upon exercise of warrant issued to purchase up to 2,046,036 shares of common stock @ $3.91/share as described in the Current Report on Form 8-K filed September 13, 2022.”Signed by Nicole Kelsey, Chief legal officer and secretary. Source: SEC Form D, newest notice filed Sep 28, 2022. Read the notice at the SEC .
equity, options SEC Jun 2020 $200 M No. 34 $50 to $250 million 53
Amyris Biotechnologies Inc.: Raise no. 34, Jun 2020 × Investors in this round 53 investors had bought by the notice of Jun 22, 2020: 53 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $200 M of $200 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $9,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer Han John Keiftenbeld · Executive Officer · Chief Financial Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James John Mccann · Director L John Doerr · Director Lisa John Qi · Director Patrick John Yang · Director Philip John Eykerman · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round JEFFERIES LLC (CRD 2347) · New York, New York Sold in all US states COWEN AND COMPANY, LLC (CRD 7616) · New York, New York Sold in all US states OPPENHEIMER & CO. INC. (CRD 249) · New York, New York Sold in all US states Remarks in the notice On the amounts: “Issuer sold 32,614,573 shares of common stock and 102,156.21 shares of Series E Convertible Preferred Stock, convertible into 34,052,070 shares of common stock, as described in Current Reports on Form 8-K filed with the SEC on June 4 and June 10, 2020.”Signed by Nicole Kelsey, General counsel and secretary. Source: SEC Form D, newest notice filed Jun 22, 2020. Read the notice at the SEC .
equity SEC Jan 2020 $94 M No. 33 $50 to $250 million 7
Amyris Biotechnologies Inc.: Raise no. 33, Jan 2020 × Investors in this round 7 investors had bought by the notice of Feb 18, 2020: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $94 M of $94 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold 13,989,973 shares of common stock and rights to purchase 18,649,961 shares of common stock, as described in a Current Report on Form 8-K filed February 6, 2020. Includes amount that may be received upon exercise of rights.”Signed by Nicole Kelsey, General counsel and secretary. Source: SEC Form D, newest notice filed Feb 18, 2020. Read the notice at the SEC .
equity, options SEC Jan 2020 $10 M No. 32 $2 to $10 million 4
Amyris Biotechnologies Inc.: Raise no. 32, Jan 2020 × Investors in this round 4 investors had bought by the notice of Jan 29, 2020: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by Issuer upon exercise of warrants issued to purchase up to 3,000,000 shares of common stock @ $3.25/share and other non-cash consideration as further described in the Current Report on Form 8-K filed January 21,2020.”Signed by Nicole Kelsey, General counsel and secretary. Source: SEC Form D, newest notice filed Jan 29, 2020. Read the notice at the SEC .
equity, options SEC Nov 2019 $4 M No. 31 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 31, Nov 2019 × Investors in this round 1 investor had bought by the notice of Dec 12, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by Issuer upon exercise of warrant issued to purchase up to 1,000,000 shares of common stock @ $3.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed December 2, 2019.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Dec 12, 2019. Read the notice at the SEC .
equity, options SEC Nov 2019 $8 M No. 30 $2 to $10 million 2
Amyris Biotechnologies Inc.: Raise no. 30, Nov 2019 × Investors in this round 2 investors had bought by the notice of Nov 29, 2019: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by Issuer upon exercise of warrants issued to purchase 2,028,423 shares of common stock @ $3.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed November 20, 2019.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Nov 29, 2019. Read the notice at the SEC .
equity, options SEC Oct 2019 $8 M No. 29 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 29, Oct 2019 × Investors in this round 1 investor had bought by the notice of Nov 12, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by issuer upon exercise of warrant issued to purchase up to 2,000,000 shares of common stock @ $3.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed November 1, 2019.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Nov 12, 2019. Read the notice at the SEC .
equity, options SEC Oct 2019 $6 M No. 28 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 28, Oct 2019 × Investors in this round 1 investor had bought by the notice of Oct 25, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by issuer upon exercise of warrant issued to purchase up to 2,000,000 shares of common stock @ $2.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed October 16, 2019.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Oct 25, 2019. Read the notice at the SEC .
equity, options SEC Sep 2019 $13 M No. 27 $10 to $50 million 3
Amyris Biotechnologies Inc.: Raise no. 27, Sep 2019 × Investors in this round 3 investors had bought by the notice of Sep 25, 2019: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $13 M of $13 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 3,205,128 shares of common stock @ $3.90/share and other non-cash consideration as further described in the Current Report on Form 8-K filed September 11, 2019.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Sep 25, 2019. Read the notice at the SEC .
equity, options SEC Aug 2019 $19 M No. 26 $10 to $50 million 1
Amyris Biotechnologies Inc.: Raise no. 26, Aug 2019 × Investors in this round 1 investor had bought by the notice of Sep 12, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $19 M of $19 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by issuer upon exercise of warrant issued to purchase 4,871,795 shares of common stock @ $3.90/share and other non-cash consideration as further described in the Current Report on Form 8-K filed September 4, 2019.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Sep 12, 2019. Read the notice at the SEC .
equity, options SEC Aug 2019 $10 M No. 25 $2 to $10 million 2
Amyris Biotechnologies Inc.: Raise no. 25, Aug 2019 × Investors in this round 2 investors had bought by the notice of Aug 29, 2019: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer John Melo · Executive Officer, Director · President and Chief Executive Officer Jonathan Neil Wolter · Executive Officer · Interim Chief Financial Officer Kathleen Valiasek · Executive Officer · Chief Business Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Frank John Kung · Director Geoffrey John Duyk · Director James Neil Mccann · Director L John Doerr · Director Lisa Neil Qi · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 3,438,829 shares of common stock @ $2.87/share and other non-cash consideration as further described in the Current Report on Form 8-K filed August 20, 2019.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Aug 29, 2019. Read the notice at the SEC .
equity, options SEC Apr 2019 $75 M No. 24 $50 to $250 million 9
Amyris Biotechnologies Inc.: Raise no. 24, Apr 2019 × Investors in this round 9 investors had bought by the notice of May 9, 2019: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $75 M of $75 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $725,300
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer Joel Cherry · Executive Officer · President of R&D John Melo · Executive Officer, Director · President and Chief Executive Officer Kathleen Valiasek · Executive Officer · Chief Financial Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Christophe John Vuillez · Director Frank John Kung · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Oppenheimer & Co. Inc. (CRD 249) · New York, New York Sold in CA Remarks in the notice On the amounts: “Issuer sold 7,356,913 shares of common stock and warrants to purchase 8,084,770 shares of common stock, as described in a Current Report on Form 8-K filed April 30, 2019. Includes amount that may be received upon exercise of warrants.”On the use of proceeds: “Proceeds from the offering may be used to pay amounts owing under a loan and security agreement with Foris Ventures, LLC, which is owned by director John Doerr.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed May 9, 2019. Read the notice at the SEC .
equity, options SEC Apr 2019 $36 M No. 23 $10 to $50 million 1
Amyris Biotechnologies Inc.: Raise no. 23, Apr 2019 × Investors in this round 1 investor had bought by the notice of Apr 30, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $36 M of $36 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer Joel Cherry · Executive Officer · President of R&D John Melo · Executive Officer, Director · President and Chief Executive Officer Kathleen Valiasek · Executive Officer · Chief Financial Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Christophe John Vuillez · Director Frank John Kung · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold 6,732,369 shares of common stock and warrants to purchase 5,424,804 shares of common stock at $2.87/share, as described in a Current Report on Form 8-K filed April 19, 2019. Includes amount that may be received upon exercise of warrants.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Apr 30, 2019. Read the notice at the SEC .
equity, options SEC Dec 2018 $60 M No. 22 $50 to $250 million 2
Amyris Biotechnologies Inc.: Raise no. 22, Dec 2018 × Investors in this round 2 investors had bought by the notice of Dec 21, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $60 M of $60 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kathleen Valiasek · Executive Officer Nicole Kelsey · Executive Officer Carole John Piwnica · Director Christoph John Goppelsroeder · Director Christophe John Vuillez · Director Frank John Kung · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Oppenheimer & Co. Inc. (CRD 249) · New York, New York Sold in CA Remarks in the notice On fees: “Represents placement agent fee. Issuer also paid an advisory fee of $600,000 in connection with the transaction.”On the amounts: “Issuer sold and issued senior convertible notes in the aggregate amount of $60M to investors under a Securities Purchase Agreement as further described in Current Reports on Form 8-K filed December 7, 2018 and December 11, 2018.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Dec 21, 2018. Read the notice at the SEC .
equity, debt, options SEC Nov 2018 $7 M No. 21 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 21, Nov 2018 × Investors in this round 1 investor had bought by the notice of Dec 4, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kathleen Valiasek · Executive Officer Nicole Kelsey · Executive Officer Carole John Piwnica · Director Christoph John Goppelsroeder · Director Christophe John Vuillez · Director Frank John Kung · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents the value of certain non-cash consideration received by the issuer as further described in the Current Report on Form 8-K filed November 26, 2018.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Dec 4, 2018. Read the notice at the SEC .
equity SEC Aug 2018 $91 M No. 20 $50 to $250 million 3
Amyris Biotechnologies Inc.: Raise no. 20, Aug 2018 × Investors in this round 3 investors had bought by the notice of Aug 31, 2018: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $91 M of $91 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer · Chief Operating Officer Joel Cherry · Executive Officer · President of R&D John Melo · Executive Officer, Director · President and Chief Executive Officer Kathleen Valiasek · Executive Officer · Chief Financial Officer Nicole Kelsey · Executive Officer · General Counsel & Secretary Carole John Piwnica · Director Christoph John Goppelsroeder · Director Christophe John Vuillez · Director Frank John Kung · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Steven John Mills · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 12,097,164 shares of common stock @ $7.52/share and other non-cash consideration as further described in the Current Report on Form 8-K filed August 20, 2018.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Aug 31, 2018. Read the notice at the SEC .
equity, options SEC Apr 2018 $38 M No. 19 $10 to $50 million 11
Amyris Biotechnologies Inc.: Raise no. 19, Apr 2018 × Investors in this round 11 investors had bought by the notice of Apr 27, 2018: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $38 M of $38 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eduardo Alvarez · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kathleen Valiasek · Executive Officer Nicole Kelsey · Executive Officer Carole John Piwnica · Director Christoph John Goppelsroeder · Director Christophe John Vuillez · Director Fernando John Reinach · Director Frank John Kung · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “Issuer paid an advisory fee of $450,000 in connection with this transaction.”On the amounts: “Includes amount that may be received by issuer upon exercise of warrants issued to purchase 3,616,174 shares of common stock @ $7.00/share and other non-cash consideration as further described in the Current Report on Form 8-K filed April 12, 2018.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Apr 27, 2018. Read the notice at the SEC .
equity, options SEC Aug 2017 $25 M No. 18 $10 to $50 million 1
Amyris Biotechnologies Inc.: Raise no. 18, Aug 2017 × Investors in this round 1 investor had bought by the notice of Aug 17, 2017: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $25 M of $25 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kathleen Valiasek · Executive Officer Nicole Kelsey · Executive Officer · Nicole Kelsey began serving as General Counsel on August 7, 2017. Bram John Klaeijsen · Director Carole John Piwnica · Director Christophe John Vuillez · Director Fernando John Reinach · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold and issued 25,000 shares of Series B preferred stock and issued warrants to purchase 3,968,116 shares of common stock to an investor under a Securities Purchase Agreement, as further described on Form 8-K filed on August 3, 2017.”Signed by Nicole Kelsey, General counsel. Source: SEC Form D and 1 amendment, newest notice filed Aug 17, 2017. Read the notice at the SEC .
equity, options SEC May 2017 $6 M No. 17 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 17, May 2017 × Investors in this round 1 investor had bought by the notice of Jun 14, 2017: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kathleen Valiasek · Executive Officer Bram John Klaeijsen · Director Carole John Piwnica · Director Christophe John Vuillez · Director Fernando John Reinach · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L. John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director R. Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold and issued 5,700 shares of Series B preferred stock and issued warrants to purchase 13,570,958 shares of common stock to an investor under a Securities Purchase Agreement, as further described on Form 8-K filed on June 6, 2017.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Jun 14, 2017. Read the notice at the SEC .
equity, options SEC May 2017 $65 M No. 16 $50 to $250 million 22
Amyris Biotechnologies Inc.: Raise no. 16, May 2017 × Investors in this round 22 investors had bought by the notice of May 23, 2017: 22 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $65 M of $65 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees $499,928
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kathleen Valiasek · Executive Officer Bram John Klaeijsen · Director Carole John Piwnica · Director Christophe John Vuillez · Director Fernando John Reinach · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L. John Doerr · Director Patrick Neil Yang · Director Philip John Eykerman · Director · Mr. Eykerman was appointed to the Board of Directors on May 18, 2017. R. Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On fees: “Placement agent fee.”On the amounts: “Issuer sold and issued 65,203.8756 shares of Series B preferred stock and issued warrants to purchase 207,954,414 shares of common stock to investors under a Securities Purchase Agreement, as further described on Form 8-K filed on May 8, 2017.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed May 23, 2017. Read the notice at the SEC .
equity, options SEC Nov 2016 $6 M No. 15 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 15, Nov 2016 × Investors in this round 1 investor had bought by the notice of Nov 30, 2016: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Raffi Asadorian · Executive Officer Abraham John Klaeijsen · Director Carole John Piwnica · Director Christophe Vuillez · Director Fernando John Reinach · Director Geoffrey John Duyk · Director Hh Sheikh Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Margo John Georgiadis · Director Patrick Neil Yang · Director R Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Offering includes amount that may be received by issuer upon exercise of warrant issued to purchase 10,000,000 shares of common stock @ $.50/share, as further described in Current Reports on Form 8-K filed November 1, 2016 and November 18, 2016.”Signed by Stephen Dobson, Assistant secretary. Source: SEC Form D, newest notice filed Nov 30, 2016. Read the notice at the SEC .
equity, options SEC Aug 2016 $3 M No. 14 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 14, Aug 2016 × Investors in this round 1 investor had bought by the notice of Aug 19, 2016: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Raffi Asadorian · Executive Officer Abraham John Klaeijsen · Director Carole John Piwnica · Director Fernando John Reinach · Director Geoffrey John Duyk · Director Hh Sheik Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Margo John Georgiadis · Director Patrick Neil Yang · Director Philippe Boisseau · Director R Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Offering includes amount that may be received by issuer upon exercise of warrant issued to purchase 5,000,000 shares of common stock @ $.50/share and other non-cash consideration, as further described in Quarterly Report on Form 10-Q filed August 9, 2016.”Signed by Chris Jaenike, Assistant secretary. Source: SEC Form D, newest notice filed Aug 19, 2016. Read the notice at the SEC .
equity, options SEC May 2016 $5 M No. 13 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 13, May 2016 × Investors in this round 1 investor had bought by the notice of May 24, 2016: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Nicholas Khadder · Executive Officer Raffi Asadorian · Executive Officer Abraham John Klaeijsen · Director Carole John Piwnica · Director Fernando John Reinach · Director Geoffrey John Duyk · Director Hh Shiek Abdullah Bin Khalifa Neil Al Thani · Director L John Doerr · Director Margo John Georgiadis · Director Patrick Neil Yang · Director Philippe Boisseau · Director R Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold and issued 4,385,964 shares of common stock at $1.14 per share under a Securities Purchase Agreement, as further described in a Current Report on Form 8-K filed on May 13, 2016.”Signed by Nicholas Khadder, Secretary. Source: SEC Form D, newest notice filed May 24, 2016. Read the notice at the SEC .
equity SEC Feb 2016 $20 M No. 12 $10 to $50 million 3
Amyris Biotechnologies Inc.: Raise no. 12, Feb 2016 × Investors in this round 3 investors had bought by the notice of Feb 25, 2016: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $20 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Nicholas Khadder · Executive Officer Raffi Asadorian · Executive Officer Abraham Klaeijsen · Director Carole Piwnica · Director Fernando Reinach · Director Geoffrey Duyk · Director HH Sheikh Abdullah bin Khalifa Al Thani · Director John Doerr · Director Margaret Georgiadis · Director Patrick Neil Yang · Director Philippe Boisseau · Director R Neil Williams · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold and issued unsecured promissory notes in the amount of $20M and warrants to purchase 2,857,142 shares of common stock to investors under a Note and Warrant Purchase Agreement, as further described on Form 8-K filed on February 19, 2016.”Signed by Nicholas Khadder, Secretary. Source: SEC Form D, newest notice filed Feb 25, 2016. Read the notice at the SEC .
debt, options SEC Jul 2015 $141 M No. 11 $50 to $250 million 2
Amyris Biotechnologies Inc.: Raise no. 11, Jul 2015 × Investors in this round 2 investors had bought by the notice of Aug 12, 2015: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $141 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Nicholas Khadder · Executive Officer Raffi Asadorian · Executive Officer Abraham John Klaeijsen · Director Fernando John Reinach · Director Geoffrey John Duyk · Director L John Doerr · Director Patrick Neil Yang · Director Philippe Boisseau · Director Piwnica John Carole · Director R Neil Williams · Director Sheikh Abdullah Bin Khalifa Neil Al Thani · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Issuer sold and issued approx. $141 million in common stock as part of exchange of convertible notes. Exchange price was $2.30 per share and Issuer also issued various warrants to Total and Temasek, as further described on Form 8-K filed on July 30, 2015.”Signed by Nicholas Khadder, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Aug 12, 2015. Read the notice at the SEC .
equity SEC Apr 2014 $4 M No. 10 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 10, Apr 2014 × Investors in this round 1 investor had bought by the notice of Apr 23, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Nicholas Khadder · Executive Officer Paulo Diniz · Executive Officer Susanna Mcferson · Executive Officer Arthur Levinson · Director Carole Piwnica · Director Fernando Reinach · Director Geoffrey Duyk · Director John Doerr · Director Nam-Hai Chua · Director Neil Williams · Director Philippe Boisseau · Director Sheikh Abdullah Bin Khalifa Al Thani · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Nicholas Khadder, General Counsel. Source: SEC Form D, newest notice filed Apr 23, 2014. Read the notice at the SEC .
equity SEC Mar 2013 $5 M No. 9 $2 to $10 million 1
Amyris Biotechnologies Inc.: Raise no. 9, Mar 2013 × Investors in this round 1 investor had bought by the notice of Apr 16, 2013: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Gary Loeb · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Paulo Diniz · Executive Officer Steven R. Mills · Executive Officer Susanna Mcferson · Executive Officer Arthur R. Levinson · Director Carole R. Piwnica · Director Fernando R. Reinach · Director Geoffrey R. Duyk · Director John R. Doerr · Director Nam-Hai R. Chua · Director Patrick R. Pichette · Director Philippe R. Boisseau · Director Ralph R. Alexander · Director Sheikh Abdullah Bin Khalifa R. Al Thani · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Gary Loeb, SVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Apr 16, 2013. Read the notice at the SEC .
equity SEC Dec 2012 $42 M No. 8 $10 to $50 million 7
Amyris Biotechnologies Inc.: Raise no. 8, Dec 2012 × Investors in this round 7 investors had bought by the notice of Jan 7, 2013: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $42 M of $42 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Gary Loeb · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Paulo Diniz · Executive Officer Peter Boynton · Executive Officer Steven R. Mills · Executive Officer Arthur R. Levinson · Director Carole R. Piwnica · Director Fernando R. Reinach · Director Geoffrey R. Duyk · Director John R. Doerr · Director Nam-Hai R. Chua · Director Neil R. Renninger · Director Patrick R. Pichette · Director Philippe R. Boisseau · Director Ralph R. Alexander · Director Sheikh Abdullah Bin Khalifa R. Al Thani · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Gary Loeb, SVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Jan 7, 2013. Read the notice at the SEC .
equity SEC May 2012 $4 M No. 7 $2 to $10 million 5
Amyris Biotechnologies Inc.: Raise no. 7, May 2012 × Investors in this round 5 investors had bought by the notice of Jun 5, 2012: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joel Cherry · Executive Officer John Melo · Executive Officer, Director Mark R. Patel · Executive Officer Paulo Diniz · Executive Officer Steven R. Mills · Executive Officer Arthur Levinson · Director Carole Piwnica · Director Fernando Reinach · Director Geoffrey R. Duyk · Director John Doerr · Director Neil Renninger · Director Patrick Pichette · Director Phillippe Boisseau · Director Ralph Alexander · Director Sheikh Abdullah bin Khalifa R. Al Thani · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Gary Loeb, SVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Jun 5, 2012. Read the notice at the SEC .
equity SEC Feb 2012 $59 M No. 6 $50 to $250 million 6
Amyris Biotechnologies Inc.: Raise no. 6, Feb 2012 × Investors in this round 6 investors had bought by the notice of Mar 12, 2012: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $59 M of $59 M offered
Smallest investment taken $499,998
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeryl Hilleman · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Mario Portela · Executive Officer Neil Renninger · Executive Officer, Director Paulo Diniz · Executive Officer Tamara Tompkins · Executive Officer Arthur Levinson · Director Carole Piwnica · Director Fernando Reinach · Director John Doerr · Director Patrick Pichette · Director Phillippe Boisseau · Director Ralph Alexander · Director Samir Kaul · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tamara Tompkins, EVP, General Counsel & Secretary. Source: SEC Form D, newest notice filed Mar 12, 2012. Read the notice at the SEC .
equity SEC Oct 2011 $7 M Issued in a merger or acquisition $2 to $10 million 1
Amyris Biotechnologies Inc.: Private sale, Oct 2011 × Investors in this round 1 investor had bought by the notice of Oct 28, 2011: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jeryl Hilleman · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Mario Portela · Executive Officer Neil Renninger · Executive Officer, Director Paulo Diniz · Executive Officer Tamara Tompkins · Executive Officer Arthur Levinson · Director Carole Piwnica · Director Fernando de Castro Reinach · Director John Doerr · Director Patrick Pichette · Director Philippe Boisseau · Director Ralph Alexander · Director Samir Kaul · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Amyris, Inc. common stock in the amount of $7,000,000 (based on closing share prices of Amyris, Inc.'s publicly traded securities) was issued as partial consideration for purchase of substantially all of the Draths Corporation's assets.”On the use of proceeds: “The offering was made as partial consideration for the purchase of substantially all of the assets of Draths Corporation by Amyris, Inc.”On a merger: “The offering was made as partial consideration for the purchase of substantially all of the assets of Draths Corporation by Amyris, Inc.”Signed by Tamara Tompkins, Executive Vice President, General Counsel, and Secretary. Source: SEC Form D, newest notice filed Oct 28, 2011. Read the notice at the SEC .
equity SEC Sep 2010 $14 M No. 5 $10 to $50 million 3
Amyris Biotechnologies Inc.: Raise no. 5, Sep 2010 × Investors in this round 3 investors had bought by the notice of Oct 12, 2010: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $14 M of $14 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jack Newman · Executive Officer Jeff Lievense · Executive Officer Jeryl Hilleman · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kinkead Reiling · Executive Officer, Director Mario Portela · Executive Officer Neil Renninger · Executive Officer Peter Boynton · Executive Officer Tamara Tompkins · Executive Officer Arthur Levinson · Director Carole Piwnica · Director Fernando Reinach · Director Geoff Duyk · Director John Doerr · Director Patrick Pichette · Director Ralph Alexander · Director Samir Kaul · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Oct 12, 2010. Read the notice at the SEC .
equity SEC Jun 2010 $133 M No. 4 $50 to $250 million 1
Amyris Biotechnologies Inc.: Raise no. 4, Jun 2010 × Investors in this round 1 investor had bought by the notice of Jul 2, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $133 M of $133 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Jack Newman · Executive Officer Jeff Lievense · Executive Officer Jeryl Hilleman · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kinkead Reiling · Executive Officer, Director Mario Portela · Executive Officer Neil Renninger · Executive Officer Peter Boynton · Executive Officer Tamara Tompkins · Executive Officer Arthur Levinson · Director Carole Piwnica · Director Fernando Reinach · Director Geoff Duyk · Director John Doerr · Director Patrick Pichette · Director Ralph Alexander · Director Samir Kaul · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Jul 2, 2010. Read the notice at the SEC .
equity SEC Mar 2010 $48 M No. 3 $10 to $50 million 1
Amyris Biotechnologies Inc.: Raise no. 3, Mar 2010 × Investors in this round 1 investor had bought by the notice of Apr 2, 2010: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $48 M of $48 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Jack Newman · Executive Officer Jeff Lievense · Executive Officer Jeryl Hilleman · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kinkead Reiling · Executive Officer, Director Neil Renninger · Executive Officer Tamara Tompkins · Executive Officer Carole Piwnica · Director Fernando Reinach · Director Geoff Duyk · Director John Doerr · Director Ralph Alexander · Director Samir Kaul · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Apr 2, 2010. Read the notice at the SEC .
equity SEC Jul 2009 $61 M No. 2 $50 to $250 million 34
Amyris Biotechnologies Inc.: Raise no. 2, Jul 2009 × Investors in this round 34 investors had bought by the notice of Apr 2, 2010: 34 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $61 M of $61 M offered
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Jack Newman · Executive Officer Jeff Lievense · Executive Officer Jeryl Hilleman · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kinkead Reiling · Executive Officer, Director Neil Renninger · Executive Officer Tamara Tompkins · Executive Officer Carole Piwnica · Director Fernando Reinach · Director Geoff Duyk · Director John Doerr · Director Ralph Alexander · Director Samir Kaul · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tamara Tompkins, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Apr 2, 2010. Read the notice at the SEC .
equity SEC Feb 2008 $2 M No. 1 $2 to $10 million 3
Amyris Biotechnologies Inc.: Raise no. 1, Feb 2008 × Investors in this round 3 investors had bought by the notice of Aug 24, 2009: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amyris Biotechnologies Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in California People named in the notice Jack Newman · Executive Officer Jeff Lievense · Executive Officer Jeryl Hilleman · Executive Officer Joel Cherry · Executive Officer John Melo · Executive Officer, Director Kinkead Reiling · Executive Officer, Director Neil Renninger · Executive Officer Tamara Tompkins · Executive Officer Fernando Reinach · Director Geoff Duyk · Director John Doerr · Director Ralph Alexander · Director Samir Kaul · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tamara Tompkins, Secretary. Source: SEC Form D, newest notice filed Aug 24, 2009. Read the notice at the SEC .
options SEC